Azithromycin suppresses human osteoclast formation and activity in vitro

Journal of Cellular Physiology

Volumn 228, Issue 5, 2013, Pages 1098-1107

  Gannon, Siobhan C ^a   Cantley, Melissa D ^a   Haynes, David R ^a   Hirsch, Robert ^a   Bartold, P Mark ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA3 INTEGRIN; CATHEPSIN K; COLONY STIMULATING FACTOR 1; GELATINASE B; MESSENGER RNA; PROTON PUMP; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ACTIN FILAMENT; ARTICLE; BONE DEVELOPMENT; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DENTIN; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

AZITHROMYCIN; BLOOD BUFFY COAT; CATHEPSIN K; CELL SURVIVAL; CYTOSKELETON; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN BETA3; LEUKOCYTES, MONONUCLEAR; MACROPHAGE COLONY-STIMULATING FACTOR; MATRIX METALLOPROTEINASE 9; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PERIODONTITIS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84873807165     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24259     Document Type: Article

References (70)

1. Aghai ZH, Kode A, Saslow JG, Nakhla T, Farhath S, Stahl GE, Eydelman R, Strande L, Leone P, Rahman I. 2007. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 62:483-488.
2. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. 2011. Immunomodulatory effects of macrolide antibiotics-Part 1: Biological Mechanisms. Respiration 81:67-74.
3. Asagiri M, Takayanagi H. 2007. The molecular understanding of osteoclast differentiation. Bone 40:251-264.
4. Bartold PM, Cantley MD, Haynes D. 2010. Mechanisms and control of pathologic bone loss in periodontitis. Periodontol 2000 53:55-69.
5. Belibasakis GN, Bostanci N. 2012. The RANKL-OPG system in clinical periodontology. J Clin Periodontol 39:239-248.
6. Belibasakis GN, Emingil G, Saygan B, Turkoglu O, Atilla G, Bostanci N. 2011. Gene expression of transcription factor NFATc1 in periodontal diseases. Acta Pathol Microbiol Immunol Scand 119:167-172.
7. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. 1989. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855-857.
8. Blandizzi C, Malizia T, Lupetti A, Pesce D, Gabriele M, Giuca MR, Campa M, Del Tacca M, Senesi S. 1999. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 70:960-966.
9. Brown LJ, Loe H. 1993. Prevalence, extent, severity and progression of periodontal disease. Periodontol 2000 2:57-71.
10. Cantley M, Fairlie D, Bartold P, Rainsford K, Le G, Lucke A, Holding C, Haynes D. 2011. Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro. J Cell Physiol 226:3233-3241.
11. Cheung PS, Si EC, Hosseini K. 2010. Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity. Ocul Immunol Inflamm 18:32-37.
12. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR. 2002. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: Semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047-1054.
13. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, Ahern MJ, Haynes D. 2003. Receptor activator NF kB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 38:380-387.
14. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. 2005. NFATc1 directly induces the human beta3 integrin gene in osteoclast differentiation. J Musculoskelet Neuron Interact 5:335-337.
15. Crotti TN, O'Sullivan RP, Shen Z, Flannery MR, Fajardo RJ, Ross FP, Goldring SR, McHugh KP. 2011. Bone matrix regulates osteoclast differentiation and annexin A8 gene expression. J Cell Physiol 226:3413-3421.
16. Day CJ, Kim MS, Stephens SR, Simcock WE, Aitken CJ, Nicholson GC, Morrison NA. 2004. Gene array identification of osteoclast genes: Differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J Cell Biochem 91:303-315.
17. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25:73-82.
18. Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J, van Erp PE. 2005. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J Invest Dermatol 124:373-383.
19. Fukushima H, Jimi E, Okamoto F, Motokawa W, Okabe K. 2005. IL-1-induced receptor activator of NF-kB ligand in in human periodontal ligament cells involves EFK-dependent PGE2 production. Bone 36:267-275.
20. Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, Ohshima T, Maeda N, Arai T. 2007a. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol 78:918-923.
21. Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N, Arai T. 2007b. Effects of full-mouth scaling and root planing in conjunction with systemically administered azithromycin. J Periodontol 78:422-429.
22. Granfar RM, Day CJ, Kim MS, Morrison NA. 2005. Optimised real-time quantitative PCR assays for RANKL regulated genes. Mol Cell Probes 19:119-126.
23. Gravallese EM. 2002. Bone destruction in arthritis. Ann Rheum Dis 61:ii84-ii86.
24. Haas AN, De Castro GD, Moreno T, Susin C, Alabandar J, Opperman RV, Rosing CK. 2008. Azithromycin as an adjunctive treatment of aggressive periodontitis: 12 months randomized clinical trial. J Clin Periodontol 35:696-704.
25. Haffajee AD. 2008. Microbiological changes associated with four different periodontal therapies for the treatment of chronic periodontitis. Oral Microbiol Immunol 23:148-157.
26. Haffajee AD, Socransky SS, Gunsolley JC. 2003. Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol 8:115-181.
27. Herrera D, Sanz M, Jepsen S, Needleman I, Roldan S. 2002. A systematic review on the effect of systematic antimicrobials as an adjunct to scaling and root planing in periodontitis patients. J Clin Periodonol 29:136-159.
28. Herrera D, Alonso B, Leon R, Roldan S, Sanz M. 2008. Antimicrobial therapy in periodontitis: The use of systemic antimicrobials against the subgingival biofilm. J Clin Periodonol 35:45-66.
29. Hirsch R. 2010. Periodontal healing and bone regeneration in response to azithromycin. Aust Dent J 55:193-199.
30. Hofbauer LC, Heufelder AE. 2001. Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243-253.
31. Hugoson A, Norderyd O, Slotte C, Thorstensson H. 1998. Distribution of periodontal disease in a Swedish adult population 1973, 1983 and 1993. J Clin Periodontol 25:542-548.
32. Iwamoto S, Kumamoto T, Azuma E, Hirayama M, Ito M, Amano K, Ido M, Komada Y. 2011. The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells. Clin Exp Immunol 166:385-392.
33. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, Goncalves RB, Valverde P, Dibart S, Li YP, Miranda LA, Ernst CWO, Izumi Y, Taubman MA. 2006. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 169:987-998.
34. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N. 2005. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 280:35209-35216.
35. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
36. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
37. Lakkakorpi PT, Vaananen HK. 1995. Cytoskeletal changes in osteoclasts during the resorption cycle. Microsc Res Tech 33:171-181.
38. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
39. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y. 2004. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 279:45969-45979.
40. Matsumura Y, Mitani A, Suga T, Kamiya Y, Kikuchi T, Tanaka S, Aino M, Noguchi T. 2011. Azithromycin may inhibit Interleukin-8 through the suppression of Rac1 and a nuclear factor kappaB pathway in KB cells stimulated with lipopolysaccharide. J Periodontol 82:1623-1631.
41. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. 2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Investig 105:433-440.
42. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT. 1999. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci 112:3985-3993.
43. Nakamura I, Takahashi N, Jimi E, Udagawa N, Suda T. 2012. Regulation of osteoclast function. Mod Rheumatol 22:167-177.
44. Nukaga J, Kobayashi M, Shinki T, Song H, Takada T, Takiguchi T, Kamijo R, Hasegawa K. 2004. Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells. J Periodontol 75:249-259.
45. Oteo A, Herrera D, Figuero E, O'Connor A, Gonzalez I, Sanz M. 2010. Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis-associated periodontitis: A pilot study. J Clin Periodontol 37:1005-1015.
46. Park CS, Park YS, Park YJ, Cho JH, Kang JM, Kim SY. 2007. The inhibitory effects of macrolide antibiotics on bone remodeling in chronic rhinosinusitis. Otolaryngol Head Neck Surg 137:274-279.
47. Polancec DS, Munic Kos, Banjanac V, Vrancic M, Cuzic M, Belamaric S, Parnham D, Polancec MJ, Erakovic D, Haber V. 2012. Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties. J Leukoc Biol 91:229-243.
48. Pradeep AR, Sagar SV, Daisy H. 2008. Clinical and microbiologic effects of subgingivally delivered 0.5% azithromycin in the treatment of chronic periodontitis. J Periodontol 79:2125-2135.
49. Ren W, Li XH, Chen BD, Wooley PH. 2004. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kB activity. J Orthop Res 22:21-29.
50. Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K. 1994. High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 124:1091-1102.
51. Sampaio E, Rocha M, Figueiredo LC, Faveri M, Duarte PM, Gomes Lira EA, Feres M. 2011. Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: A randomized placebo-controlled clinical trial. J Clin Periodontol 38:838-846.
52. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108.
53. Sefton AM. 1999. Macrolides and changes in the oral flora. Int J Antimicrob Agents 11:S23-S29; discussion S31-S22.
54. Sefton AM, Maskell JP, Beighton D, Whiley A, Shain H, Foyle D, Smith SR, Smales FC, Williams JD. 1996. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 23:998-1003.
55. Smith SR, Foyle DM, Daniels J, Joyston-Bechal S, Smales FC, Sefton A, Williams J. 2002. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: Clinical results. J Clin Periodontol 29:54-61.
56. Soysa NS, Alles N, Shimokawa H, Jimi E, Aoki K, Ohya K. 2009. Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity. J Bone Miner Metab 27:131-139.
57. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. 2007. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 313:168-178.
58. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. 2004. Human primary osteoclasts: In vitro generation and applications as pharmacological and clinical assay. J Transl Med 2:6.
59. Takayanagi H. 2007. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 1116:227-237.
60. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901.
61. Tiranathanagul S, Yongchaitrakul T, Pattamapun K, Pavasant P. 2004. Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. J Periodontol 75:1647-1654.
62. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. 2007. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35:W71-W74.
63. Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, Stupin Polancec D, Belamaric D, Parnham MJ, Erakovic Haber V. 2012. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol 165:1348-1360.
64. Wada N, Maeda H, Yoshimine Y, Akamine A. 2004. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 35:629-635.
65. Wilson SR, Peters C, Saftig P, Bromme D. 2009. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 284:2584-2592.
66. Yamaguchi M, Ukai T, Kaneko T, Yoshinaga M, Yokoyama M, Ozaki Y, Hara Y. 2008. T cells are able to promote lipopolysaccharide-induced bone resorption in mice in the absence of B cells. J Periodontal Res 43:549-555.
67. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF. 2007. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282:18245-18253.
68. Yashima A, Gomi K, Maeda N, Arai T. 2009. One-stage full-mouth versus partial-mouth scaling and root planing during the effective half-life of systemically administered azithromycin. J Periodontol 80:1406-1413.
69. Yongchaitrakul T, Lertsirirangson K, Pavasant P. 2006. Human periodontal ligament cells secrete macrophage colony-stimulating factor in response to tumor necrosis factor-alpha in vitro. J Periodontol 77:955-962.
70. Zou W, Teitelbaum SL. 2010. Integrins, growth factors, and the osteoclast cytoskeleton. Ann N Y Acad Sci 1192:27-31.